Thousands of people in England suffering from severe dust mite allergies will soon have access to a daily pill that offers long-term relief. The National Institute for Health and Care Excellence (NICE) has approved Acarizax, a first-of-its-kind sublingual immunotherapy designed to increase the body’s resistance to dust mites.
A Groundbreaking Treatment
Acarizax, developed by ALK-Abelló, is the first NICE-approved treatment for moderate to severe house dust mite allergic rhinitis. It is particularly beneficial for individuals aged 12 to 65 who have persistent allergy symptoms unresponsive to standard treatments, such as steroid nasal sprays and antihistamines.
By taking a fixed amount of house dust mite extract daily, the body gradually becomes less sensitive to allergens, reducing symptoms over time. The treatment is taken for three years at home, eliminating the need for frequent hospital visits.
A Common Yet Debilitating Allergy
House dust mites are tiny creatures that thrive in bedding, carpets, and soft furnishings, feeding on dead skin cells. Despite regular cleaning, complete eradication is impossible, leading to persistent allergic reactions.
Common symptoms include:
- Sneezing, itchy nose, and nasal congestion
- Runny or blocked nose
- Itchy, red, and watery eyes
- Severe cases causing facial swelling, fatigue, and sleep disturbances
Persistent allergic rhinitis affects individuals four or more days a week for over a month, significantly impacting daily life, work, and school attendance.
Expert Reactions and Patient Benefits
Helen Knight, NICE’s director of medicines evaluation, emphasized the positive impact Acarizax can have:
“This is a chronic, debilitating condition that can prevent people from going to work or school. This medicine has been found to improve symptoms, helping people live their lives, and has the potential to be truly life changing.”
GP and patient expert Dr. Helen Evans-Howells also welcomed the approval, stating:
“This drug could be life-changing for those affected by severe symptoms like fatigue, congestion, and facial swelling. The evidence clearly shows it offers an effective solution for those who have struggled with standard treatments.”
Amena Warner, head of clinical services at Allergy UK, called the decision a “landmark step”, highlighting the mental and physical toll that severe allergies impose.
“Many endure years of misery—nasal congestion, sneezing, and sleep disturbances—with little respite. This treatment brings new hope to patients who have long struggled with their condition.”
How Acarizax Works
Unlike conventional treatments that only mask symptoms, Acarizax targets the root cause by retraining the immune system. The sublingual tablet, which dissolves under the tongue, gradually builds long-term tolerance to dust mites, reducing the severity and frequency of allergic reactions.
Key advantages:
- First treatment tackling the underlying cause
- Long-term symptom relief
- No need for frequent hospital visits
- Taken conveniently at home
Who Qualifies for the Treatment?
To be eligible for Acarizax, patients must:
- Be aged 12 to 65 years
- Have moderate to severe house dust mite allergic rhinitis
- Show symptoms persisting despite antihistamines or nasal steroids
- Undergo an allergy test (skin prick or specific IgE test)
A Step Toward Equitable Allergy Care
Previously available only as a private treatment, Acarizax’s approval on the NHS removes financial barriers for thousands of eligible patients.
Simone Miles, CEO of Allergy UK, noted:
“For too long, people with dust mite allergies have had no choice but to adopt exhausting cleaning regimens just to feel safe at home. Now, with Acarizax accessible through the NHS, patients will no longer need to rely on costly private treatments.”
Final Thoughts
Acarizax marks a major breakthrough in allergy care, offering hope and relief to thousands of people whose lives are disrupted by severe dust mite allergies. With expert backing and clinical trials proving its effectiveness, this life-changing treatment is set to improve the quality of life for many across England.
